Two clinically proven examples include the Abl, PDGFRβ and Kit inhibitor imatinib and the EGFR/HER2 inhibitor erlotinib, both of which have demonstrated additive anti-cancer effects when used in combination with HDAC inhibitors [74,75,76,77]. Here, EGFR is linked to cancer.